Peptide
Reference library
Educational peptide reference — research use only.
Research & educational use only
For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.
The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.
Liraglutide
A GLP-1 receptor agonist studied in diabetes and obesity research.
- Half-life (approx.)
- ~13 h (approx., subQ)
- Diluent
- Pre-mixed pen
- Common vials
- 3, 6 mg
Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.
Overview
Liraglutide is a daily GLP-1 receptor agonist with 97% homology to native GLP-1, studied in diabetes and obesity trials (Victoza/Saxenda). Research compares its efficacy and GI side-effect profile to newer weekly analogs. Once-daily acylated GLP-1 analog with LEADER cardiovascular outcome data.
Structure & identity
GLP-1(7-37) analog with C16 fatty-acid side chain
Status: FDA-approved (Victoza, Saxenda).
Mechanism
Liraglutide activates GLP-1 receptors with fatty-acid mediated albumin binding, prolonging half-life for once-daily subcutaneous dosing in published trials.
Acylated GLP-1 analog with albumin binding for once-daily DPP-4-resistant receptor activation. Albumin binding via C16 fatty-acid side chain extends half-life versus native GLP-1.
Studies & clinical programs
LEADER cardiovascular outcomes(Phase 3)
Type 2 diabetes with high CV risk
- Cardiovascular safety and MACE endpoints evaluated in long-term follow-up.
Source: LEADER trial
SCALE obesity program(Phase 3)
Adults with overweight or obesity
- Daily GLP-1 dosing with C16 acylation for albumin binding documented weight-loss endpoints.
Research models in literature
- LEADER CV trial
- SCALE obesity program
Literature highlights
- Acylated GLP-1 analog studied in LEADER cardiovascular and SCALE obesity programs.
- Once-daily albumin-binding extends half-life versus native GLP-1 in PK trials.
- HbA1c, weight, and CV outcome endpoints well characterized in published trials.
Key targets & pathways
Research areas
Routes in research literature
Also known as
Stability & storage phases
| Phase | Condition | Guidance |
|---|---|---|
| Lyophilized | Sealed vial, refrigerated (2–8 °C) | Intact lyophilized cake or powder is typically stable for months to years per published stability data; protect from moisture, light, and repeated freeze-thaw of the dry vial. |
| Reconstituted | Bacteriostatic water (0.9% benzyl alcohol), refrigerated | Most aqueous peptide solutions remain usable for approximately 2–4 weeks refrigerated; verify published stability data and label with reconstitution date. |
| Working aliquots | Pre-drawn syringes or microtubes, frozen (−20 °C) | Aliquot promptly after mixing to limit freeze-thaw cycles on the main vial; thaw once and use to reduce protease-mediated degradation. |
Stability windows are formulation-dependent — verify published data and your lab SOP.
Reconstitution reference table
| Vial (mg) | Diluent (mL) | mcg/mL | Units @ 100 mcg | Units @ 250 mcg | Units @ 500 mcg |
|---|---|---|---|---|---|
| 3 | 0.5 | 6000.0 | 1.7 | 4.2 | 8.3 |
| 6 | 0.5 | 12000.0 | 0.8 | 2.1 | 4.2 |
U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.
Reconstitution steps
- Allow vial to reach room temperature (15–30 min)
- Swab rubber stopper with alcohol prep pad
- Draw calculated bacteriostatic water into syringe
- Inject diluent slowly down vial wall — do not spray directly onto cake
- Gently swirl until fully dissolved — do not shake vigorously
- Label with date, concentration, and diluent volume
- Refrigerate and use within your lab stability window
Often supplied pre-mixed; research powder formulations vary.
Laboratory record checklist
- Compound identity recorded in lab notebook (name, lot, preparation date)
- Analytical identity cross-checked against published sequence or structure
- Potency or concentration documented from analytical certificate when available
- Purity or HPLC data filed when provided with research material
- Appearance noted: intact lyophilized cake or uniform powder
- Sterility / endotoxin report archived when available
- Storage temperature applied immediately per published stability guidance